- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company, is pleased to announce that it is scheduled to ...
Paradigm and Film2Future have inked a two-year collaborative agreement that will see the talent agency become the exclusive partner of the non-profit that promotes pathways into the entertainment ...
Paradigm Talent Agency has closed a two-year deal with Film2Future, a non-profit professional-level filmmaking program for under-served teenagers in Los Angeles aged 14-18, to introduce the ...
SAN FRANCISCO--(BUSINESS WIRE)--Homeward ®, a company committed to rearchitecting the delivery of health and care in partnership with communities everywhere, starting in rural America, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results